UCB SA (OTCMKTS:UCBJY) Sees Large Drop in Short Interest

UCB SA (OTCMKTS:UCBJY) saw a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 5,769 shares, a drop of 73.8% from the June 15th total of 21,989 shares. Based on an average trading volume of 70,017 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are sold short.

Analyst Ratings Changes

A number of analysts have issued reports on UCBJY shares. Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 15th. Zacks Research upgraded shares of UCB from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, Jefferies Financial Group raised shares of UCB to a “moderate sell” rating in a research note on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, UCB currently has a consensus rating of “Moderate Buy”.

UCB Price Performance

UCBJY stock traded down $0.91 during mid-day trading on Monday, reaching $135.00. The company had a trading volume of 32,657 shares, compared to its average volume of 36,140. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. The firm has a fifty day simple moving average of $144.02 and a 200 day simple moving average of $148.05. UCB has a fifty-two week low of $98.24 and a fifty-two week high of $168.76.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.